ION expands ETF trading capabilities with Tradeweb integration
Artivion, INC. (NASDAQ:AORT) SVP, Clinical & MD Affair, Marshall S. Stanton, sold a total of $2,133,920 in company stock on November 21, 2025. The sales involved 47,376 shares of common stock, sold in multiple transactions with prices ranging from $44.91 to $45.346.
On the same day, Stanton also exercised options to acquire a total of 47,376 shares of Artivion common stock for a total value of $672,987. These transactions were executed at prices of $11.03 and $18.44. While Artivion isn’t currently profitable (with -$0.21 EPS for the last twelve months), InvestingPro analysis shows analysts expect the company to turn profitable this year with a forecasted EPS of $0.63. Discover 15 more key insights and a comprehensive Pro Research Report on AORT with an InvestingPro subscription.
In other recent news, Artivion Inc. reported impressive third-quarter earnings for 2025, surpassing market expectations with an earnings per share (EPS) of $0.16, compared to the forecasted $0.03. The company also posted revenues of $113.4 million, exceeding the anticipated $110.44 million. Following these strong results, Artivion raised its revenue and EBITDA guidance for the full year 2025. Analysts have responded positively to these developments, with Oppenheimer raising its price target for Artivion to $50 while maintaining an Outperform rating. Similarly, Needham increased its price target to $58, keeping a Buy rating on the stock. Artivion’s third-quarter revenue grew 16% year-over-year on a pro-forma, constant-currency basis, surpassing both Oppenheimer’s estimate of $112 million and the consensus estimate of $110 million. These recent developments have positioned Artivion favorably in the eyes of analysts and investors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.